Dr. Lucy Gildea, Mary Kay’s Chief Scientific Officer
DALLAS, TX – (September 23, 2020) – The Mary Kay FoundationSM, a decades-long leader in the mission to eliminate cancers affecting women, recently announced Dr. Lucy Gildea, Mary Kay’s Chief Scientific Officer, will join the Baylor Scott & White Dallas Foundation Board as well as the Baylor Scott & White Charles A. Sammons Cancer Center Board of Advisors.
Led by board chairman Norm Bagwell, Baylor Scott & White Dallas Foundation Board members lend their time and talents to help shape the direction of the Foundation and serve as ambassadors of the Baylor Scott & White Health mission to promote the well-being of all individuals, families and communities. Formed in 1978 with the sole purpose of generating charitable support for Baylor Scott & White in North Texas, the Dallas Foundation has disbursed more than $820 million to Baylor Scott & White in support of clinical care, research, education and capital needs.
“Our new board members include individuals like Dr. Gildea who bring a wealth of experience and expertise in their fields and who will be tremendous assets to the Foundation as we further our mission,” said Kristi Sherrill Hoyl, interim president of Baylor Scott & White Dallas Foundation and Chief Policy and Community Affairs Officer for Baylor Scott & White Health. “Working together, we are helping drive positive change and improving the health of the North Texas communities served by Baylor Scott & White. We are thrilled to have their incredible leadership.”
The Baylor Scott & White Charles A. Sammons Cancer Center Board of Advisors is focused on providing counseling strategy, fundraising, community linkage, and political influence to oncology care and services at Baylor Scott & White Sammons Cancer Center and Baylor Scott & White T. Boone Pickens Cancer Hospital. Together, the cancer facilities, located at Baylor University Medical Center at Dallas, comprise one of the largest cancer treatment centers in the U.S. Sammons Cancer Center is also an innovative leader in cancer research, participating in nearly 250 active clinical trials, and providing new immunotherapies that re-engineer a patient’s immune cells to fight cancer.
“I am honored to join the Baylor Scott & White Dallas Foundation Board and Baylor Scott & White Sammons Cancer Center Advisory Board with individuals from diverse professions,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc. “By connecting the cancer research, treatments and advancements with the community, we can enhance awareness of the incredibly innovative work being done to fight cancer.”
Over the course of more than two decades, The Mary Kay FoundationSM has awarded more than $80 million to women’s shelters and domestic violence service providers, as well as cancer research programs and related causes throughout the United States.